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ABSTRACT
Diagnosis of cardiac sarcoidosis is often challenging. Whereas cardiac magnetic 
resonance imaging (CMR) and positron emission tomography/computed tomography 
(PET/CT) with 18F-fluorodeoxyglucose (FDG) are most commonly used to evaluate 
patients, PET/CT using radiolabeled somatostatin receptor (SSTR) ligands for 
visualization of inflammation might represent a more specific alternative. This study 
aimed to investigate the feasibility of SSTR–PET/CT for detecting cardiac sarcoidosis 
in comparison to CMR.
15 patients (6 males, 9 females) with sarcoidosis and suspicion on cardiac 
involvement underwent SSTR-PET/CT imaging and CMR. Images were visually scored. 
The AHA 17-segment model of the left myocardium was used for localization and 
comparison of inflamed myocardium for both imaging modalities. In semi-quantitative 
analysis, mean (SUVmean) and maximum standardized uptake values (SUVmax) of 
affected myocardium were calculated and compared with both remote myocardium 
and left ventricular (LV) cavity.
SSTR-PET was positive in 7/15, CMR in 10/15 patients. Of the 3 CMR+/PET- 
subjects, one patient with minor involvement (<25% of wall thickness in CMR) was 
missed by PET. The remaining two CMR+/PET- patients displayed no adverse cardiac 
events during follow-up.
In the 17-segment model, PET/CT yielded 27 and CMR 29 positive segments. 
Overall concordance of the 2 modalities was 96.1% (245/255 segments analyzed). 
SUVmean and SUVmax in inflamed areas were 2.0±1.2 and 2.6±1.2, respectively. The 
lesion-to-remote myocardium and lesion-to-LV cavity ratios were 1.8±0.2 and 1.9±0.2 
for SUVmean and 2.0±0.3 and 1.7±0.3 for SUVmax, respectively.
Detection of cardiac sarcoidosis by SSTR-PET/CT is feasible. Our data warrant 
further analysis in larger prospective series.
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INTRODUCTION
Sarcoidosis is a multisystem granulomatous disorder 
of unknown etiology that can virtually involve all organ 
systems [1]. Whereas lymph nodes and lungs are most 
commonly affected, cardiac involvement is present in up 
to one third of patients [2, 3] and has been reported as the 
second leading cause of death by sarcoidosis in the United 
States and the leading cause in Japan [4]. Therefore, 
early diagnosis and treatment initiation is mandatory. 
However, diagnosis is often challenging due to the patchy, 
multifocal pattern of the disease rendering sensitivity of 
endomyocardial biopsy as low as 20-30% [5]. In clinical 
routine, the Guidelines of the Japanese Ministry of Health 
and Welfare (JMHWG) and the Heart Rhythm Society 
(HRS) serve as a standard for the diagnosis of cardiac 
sarcoidosis (CS) and include a combination of clinical and 
imaging findings, such as ECG abnormalities and signs of 
acute myocardial damage on established cardiac imaging 
techniques [6, 7]. In terms of cardiac imaging, both 
cardiac magnetic resonance imaging (CMR) and positron 
emission tomography/computed tomography (PET/
CT) with 18F-fluorodeoxyglucose (FDG) have proven its 
value for CS detection and patient prognostication [2, 
8–10]. However, specificity of FDG-PET is hampered 
by physiologic tracer accumulation requiring dedicated 
patient preparation [11–13]. As a more specific alternative, 
feasibility of PET targeting the somatostatin receptor 
(SSTR) subtype 2 has been demonstrated for imaging 
atherosclerosis [14–16], myocardial inflammation [17] 
and CS [18]. The aim of this study was to further assess 




All but one patient (Patient #9) presented with 
biopsy-proven sarcoidosis. Most commonly, mediastinal 
und hilar lymph nodes (n=13) and the lungs (n=14) were 
affected. Other sites of organ involvement included spleen 
(n=2), liver (n=2), skin (n=2), bone (n=1), parotic glands 
(n=1), omentum (n=1), uvea (n=1) and the nasal sinuses 
(n=1).
Cardiac involvement was suspected due to (a 
mixture of) typical clinical symptoms such as frequent 
palpitations and/or supra- and ventricular premature beats 
in long-term holter monitoring (n=6), aberrant rest ECG 
findings including bifascicular blocks (n=5), ventricular 
tachycardia (n=2), severe or otherwise unexplainable heart 
failure (n=5) or shortness of breath (n=3). Two patients 
initially presented with both acute chest pain and elevated 
cardiac enzymes. Coronary artery disease was excluded in 
these patients invasively. Two patients had biopsy-proven 
cardiac involvement and were referred for follow-up 
examinations.
At the time of imaging, 11/15 patients were 
treatment-naïve. Patient #5 presented with corticosteroids 
and azathioprine due to extensive pulmonary involvement, 
patients #6, #11, and #14 were treated with prednisolone. 
During follow-up, four patients developed severe 
ventricular tachycardia that required the implantation of 
an ICD (n=2) or protection by a life vest (n=2). All other 
patients had no cardiac events. However, six subjects were 
started on immunosuppressive therapy (after imaging).
A concise overview of patients′ characteristics can 
be found in Table 1.
Imaging results
On visual inspection, SSTR-PET/CT returned 
positive findings in 7/15, CMR in 10/15 patients. Of 
the 3 CMR+/PET- subjects, one patient (patient #3) with 
minor involvement (<25% of wall thickness in CMR) was 
missed by PET, most likely due to partial volume effects 
and the rather modest intensity of the tracer signal. The 
remaining two CMR+/PET- patients (patients #11 and #14) 
displayed no adverse cardiac events during follow-up, 
and repeated CMR imaging revealed stable morphologic 
myocardial changes. In total, both modalities returned 
concordant results in 12/15 subjects.
In a total of 255 segments analyzed, there were 
27 segments positive in 68Ga-DOTA-TOC-PET/CT and 
29 segments positive in CMR, respectively. Overall, 
retention of the radiotracer 68Ga-DOTA-TOC was rated 
mild or moderate and no segment was rated intense (mild 
retention in 11/27 (41%) segments; moderate retention, 
16/27; 59%). Typical PET-findings illustrating enhanced 
tracer uptake in both a patient with extensive (patient #8) 
as well as a subject without cardiac involvement (patient 
#6; positive mediastinal lymph nodes present) are given in 
Figure 1 and Figure 2, respectively.
On a head-to-head comparison, SSTR-PET and 
CMR were concordantly positive in 23 segments (23/29 
segments positive at CMR; 79.3%). 4 segments were 
SSTR-PET positive and MRI-negative (1.6%; 4/255), 
6 SSTR-PET negative and MRI-positive (2.4%; 6/255). 
Both modalities returned negative results in 222 segments, 
thus leading to an overall concordance of 96.1% (Table 2). 
The individual results of the 17-segment analysis for both 
sub-groups can be inferred from Supplementary Figure S1.
Semi-quantitative analysis
SUVmean and SUVmax were significantly higher in the 
inflamed myocardium as compared to remote myocardium 
or the left ventricular (LV) cavity. SUVmean in inflamed 
areas ranged from 1.3-4.5 (mean, 2.0±1.2) and SUVmax 
from 1.4-5.0 (mean, 2.6±1.2), respectively. The SUVmean 
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ratios of lesion-to-remote myocardium were 1.8±0.2 
and for lesion-to-LV cavity 1.9±0.2. The corresponding 
SUVmax ratios were 2.0±0.3 and 1.7±0.3, respectively.
DISCUSSION
To our knowledge, this is the first study to assess 
the performance of SSTR-directed PET/CT in comparison 
to CMR in cardiac sarcoidosis. General feasibility of 
somatostatin receptor targeted imaging of inflammatory 
cells in sarcoidosis by means of 111In-labeled pentetreotide 
had already been demonstrated in the late 90s [19, 20]. 
Our group previously reported on the suitability of SSTR-
PET/CT in a single patient with septal involvement of 
sarcoidosis [18]. In this two-center study, we were able 
to confirm previous results. SSTR-PET/CT identified 
myocardial uptake consistent with inflammatory 
activity of sarcoid granulomas in 7/15 patients, thereby 
demonstrating high concordance with CMR. Distribution 
of the radiotracer matched with CMR late-gadolinium-
enhancement and T2-weighted edema, demonstrating focal 
accumulation within areas of myocardial inflammation in 
23 of 29 involved segments (79%).
On a patient basis, one patient with minor 
involvement (<25% of wall thickness in CMR) was 
missed, most likely due to partial volume effects and 
the rather modest intensity of the tracer signal. The 
remaining two CMR+/PET- patients displayed no adverse 
cardiac events during follow-up. Of note, repeated CMR 
imaging revealed stable morphologic myocardial changes 
consistent with chronic post-inflammatory processes.
Though tracer uptake in damaged myocardium was 
almost twice as high as compared to the background of the 
left ventricular cavity or remote unaffected myocardium, 
Table 1: Patients’ characteristics
No. Age Sex Sites ofsarcoidosis Clinical findings
68Ga-
DOTATOC CMR(T2/LGE) Clinical follow-up
1 47 F LN, lung Palpitations negative negative/negative unremarkable
2 54 F LN, lung Bifascicular block, cardiac enzymes, HF, VPB positive positive/positive VT, ICD
3 52 M LN, lung Cardiac enzymes,chest pain negative positive/positive
Initiation of 
corticosteroids
4 41 M Lung Palpitations negative negative/negative unremarkable
5 52 F LN, lung Palpitations, SOB negative negative/negative unremarkable








8 42 F Bone, LN, liver,lung, spleen HF, RBBB positive positive/positive VT, cardiogenic shock
9 60 F - HF, LBBB negative negative/negative unremarkable
10 42 M LN, lung, skin VT positive positive/positive VT, ICD
11 55 F LN, liver, lung, omentum HF, LBBB negative positive/positive unremarkable
12 65 M LN, lung, parotidea, uvea VPB positive positive/positive unremarkable
13 52 M LN, lung Known CS positive positive/positive unremarkable
14 71 F LN, lung, skin Known CS negative positive/positive unremarkable
15 25 F LN, lung VT, HF positive positive/positive VT, lifevest
CS = cardiac sarcoidosis, F = female, HF = heart failure, ICD = implantable cardioverter defibrillator, LAFB = left anterior 
fascicular block, LN = lymph nodes, M = male, RBBB = right bundle branch block, SOB = shortness of breath, VPB = 
ventricular premature beats, VT = ventricular tachycardia
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Figure 1: Display of a patient with active myocardial sarcoidosis. Consistency of 68Ga-DOTATOC-PET and CMR Display 
of transaxial 68Ga-DOTATOC-PET (A., color bar indicating standardized uptake values), fused PET/CT B., short-axis late gadolinium 
enhanced (LGE) (C., insert: corresponding PET slice), and short-axis T2-weighted CMR D. slices in a 42-year-old woman (patient #8) 
with multi-organ sarcoidosis. PET presents enhanced tracer uptake in large portions of the left ventricle, highly consistent with cardiac 
involvement of sarcoidosis. CMR yields corresponding results. Of note, the patient experienced sustained ventricular tachyarrhythmia with 
subsequent cardiogenic shock five days after somatostatin-directed imaging requiring mechanical circulatory support with a percutaneous 
microaxial blood pump and veno-arterial extracorporeal membrane oxygenation.
Figure 2: Display of a patient without myocardial sarcoidosis. Consistency of 68Ga-DOTATOC-PET and CMR Display of 
transaxial 68Ga-DOTATOC-PET (A., color bar indicating standardized uptake values), fused PET/CT B., short-axis late gadolinium 
enhanced (LGE) C., and short-axis T2-weighted CMR D. slices in a 51-year-old woman (patient #6) with multi-organ sarcoidosis. PET 
presents enhanced tracer uptake in a left axillary and mediastinal lymph nodes, highly consistent with active sarcoidosis. In correspondence 
to CMR, no signs of myocardial involvement can be recorded. Follow-up is unremarkable regarding cardiac events.
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SUVmax of sarcoid lesions ranged between 1.4 and 5.0 
and were therefore much lower than those reported for 
18F-FDG [21, 22]. However, since the myocardium does 
not display any physiologic 68Ga-DOTATOC uptake, 
tracer retention in the heart can be considered specific. 
Interestingly, in one patient in whom both 18F-FDG- and 
68Ga-DOTATOC-PET were available in addition to CMR 
(patient #10), 18F-FDG failed to detect active inflammation 
whereas both SSTR-PET and CMR returned findings 
highly consistent with sarcoidosis. Clinically, the patient 
developed ventricular tachyarrhythmia the day after CMR.
As another advantage, SSTR-directed imaging 
obviates the need to adhere to specific patient preparation 
protocols including prolonged fasting, ingestion of low-
carbohydrate, high-fat meals or the injection of heparin 
prior to radiotracer injection [12, 13, 23].
Up to now, only few studies have addressed the 
value of SSTR-PET/CT for the imaging of cardiovascular 
inflammation with most reports focusing on the detection 
of atherosclerosis [14–16].
In its translation to cardiac sarcoidosis, this approach 
might allow for direct assessment of disease activity, 
especially in the course of treatment. While the current 
gold standard MRI depicts structural changes like cardiac 
damage and scarring and edema with the highest spatial 
resolution, 68Ga-DOTATOC uptake may directly reflect the 
underlying immunological cell activity. In future, given 
the complementary nature of PET and MRI signals, the 
combination of the two may be the optimal diagnostic 
approach, preferably by integrated MRI/PET.
Additionally, whereas a recent study comparing 
68Ga-DOTANOC and 18F-FDG PET/CT has demonstrated 
encouraging diagnostic accuracy for SSTR-directed PET 
[24], the prognostic value of 68Ga-DOTATOC PET/CT, 
especially in comparison to 18F-FDG has to be clarified in 
future trials. Whereas higher quantitative 18F-FDG uptake 
in CS patients with ventricular tachycardia than in those 
with atrioventricular block and asymptomatic controls 
and a higher risk of death or ventricular tachycardia as 
compared to JMHWG criteria or the ejection fraction 
have been reported for 18F-FDG [9, 25], nothing is 
known about patient prognostication by SSTR-PET/CT 
so far. Interestingly, one patient with extensive cardiac 
involvement (patient #6) experienced sudden malignant 
ventricular tachycardia with subsequent cardiogenic shock 
requiring mechanical circulatory support. Although no 
conclusions can be drawn from a single example in this 
patient cohort, the extent of SSTR-PET+ myocardial areas 
might provide the same prognostic information as shown 
for 18F-FDG-PET/CT, given that somatostatin receptor-
directed PET directly targets the underlying inflammatory 
cells.
Our work has several limitations. Most importantly, 
histopathologic proof of sarcoid granulomas and SSTR 
expression as the adequate reference test was not available. 
Cardiac gating for PET imaging was not performed. Early 
contrast enhancement CMR studies were not included. 
Data on short-term reproducibility of our findings are 
missing and should be the subject of subsequent work.
In conclusion, imaging of cardiac sarcoidosis using 
SSTR-targeted PET/CT is feasible. Our pilot data warrant 
further analysis in a larger prospective series.
MATERIALS AND METHODS
Subjects and study design
A total of 15 patients (6 males and 9 females, median 
age, 52 years: range, 22-80 years) with histologically 
proven sarcoidosis (14/15) and the clinical suspicion of 
cardiac involvement underwent both SSTR-PET/CT as 
well as CMR on a compassionate use base at the German 
University Centers of Bonn and Würzburg. No patient 
had a current or prior history of cardiac disease (e.g. prior 
infarction, myocarditis or cardiomyopathy). Imaging was 
performed within a median of 27 days (range, 1-57 days).
German federal laws accept the use of the radiotracer 
68Ga-DOTA-TOC under conditions of the pharmaceutical 
law. Written informed consent was obtained prior to the 
study from all patients.
Preparation of 68Ga-DOTATOC
In Würzburg, 68Ga–DOTATOC was prepared 
using a modification of the method described previously 
by Breeman et al. [26] using a SCINTOMICS module 
(Scintomics, Fürstenfeldbruck, Germany). The synthesis 
was carried out on a computer-assisted synthesis module 








positive 23 4 27
negative 6 222 228
∑ 29 226 255
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(Scintomics, Fürstenfeldbruck, Germany). The labeling 
procedure was optimized concerning amount of peptide, 
reaction time and reaction temperature. Radiochemical 
purity was determined by gradient HPLC (Scintomics, 
Fürstenfeldbruck, Germany).
In Bonn, an improved manual method developed by 
Eppard and colleagues was used [27].
PET imaging
PET scans were acquired using an integrated 
PET/CT scanner (Siemens Biograph 2 [Bonn], Siemens 
Biograph mCT 64 [Würzburg], Siemens, Knoxville, USA) 
consisting of a LSO full-ring PET and a 2 or 64-slice spiral 
CT. 124±31 MBq of 68Ga-DOTA-TOC were injected. 
After a period of 60 min, transmission data were acquired 
using low-dose CT of the thorax (16 mAs, 130 kV, 512 x 
5215 matrix, 5 mm slice thickness, increment of 15 mm/s, 
rotation time of 0.8 s, and pitch index of 1.2 [Bonn], 80 
mAs, 120 kV, 512 × 512 matrix, 5mm slice thickness, 
increment of 30 mm/s, rotation time of 0.5s, and pitch 
index of 0.8 [Würzburg]). Consecutively, PET emission 
data of the heart were acquired in three-dimensional mode 
over 10 minutes. PET data were reconstructed into a 128 
x 128 [Bonn] or 200 × 200 [Würzburg] matrix using the 
iterative algorithm implemented by the manufacturer 
including decay and scatter correction based on the 
acquired CT data.
Images were first inspected visually by two 
experienced nuclear medicine physicians (CL and 
AKB; RAB and FCG, respectively). For quantification 
of increased tracer uptake, a visual score using the 
terms “mild”, “moderate” and “intense” was used. 
Areas of increased 68Ga-DOTATOC accumulation were 
documented using the 17-segment AHA heart model [28].
For semi-quantitative analysis, the axial PET image 
slice with maximum cardiac uptake was selected. A 
standardized 15mm circular region was placed over the 
area with the peak activity. This first ROI was used to 
derive maximum (SUVmax) and mean standardized uptake 
values (SUVmean). SUVmax and SUVmean were also derived 
in normal reference regions defined by two distinct 
methods: (1) a second ROI (diameter of 15 mm) in a 
remote region of the left ventricular wall (not supplied by 
the culprit vessel) without late-gadolinium-enhancement 
(LGE) in the corresponding MRI data (if applicable) 
and (2) another ROI with a diameter of 25 mm in the 
left ventricular cavity. Signal-to-background ratios were 
calculated for each method.
CMR imaging
CMR was performed on a 1.5 T (n=12, Achieva 
1.5T, Philips Healthcare, Best, The Netherlands) and 
3.0T (n=3, Achieva DS 3.0T, Philips Healthcare, Best, 
The Netherlands) scanner using dedicated phased array 
coil for radiofrequency reception. Sequences were gated 
to the heart cycle via a four lead vector cardiogram. The 
protocol included a morphologic study based on balanced 
turbo field echo sequences for documentation of standard 
cine long and short axis views (FOV 380 mm, flip angle 
60°, TE 2.6 – 3.0 ms, TR 130-158 ms). A T2-weighted 
multi echo gradient echo sequence was used for imaging 
myocardial edema in both long and short axis (FOV 370 
ms, NSA 2, TE 90 ms, TR 2000 -3600 ms, TR (beats) 3). 
Late enhancement imaging was performed 9 to 12 min 
after antecubital intravenous administration of 0.15 mmol/
kg of a gadolinium based contrast agent (Gadobutrol, 
Bayer HealthCare, Leverkusen, Germany). An inversion 
recovery T1 turbo field echo sequence was used, and 
the inversion time was adjusted to completely null the 
myocardial signal.
Image analysis was performed using the Extended 
Workspace software (EWS, Philips Healthcare, Best, The 
Netherlands). In analogy to PET, all LGE and T2-weighted 
scans were segmentally analyzed with regards to scar and 
edema distribution within the myocardium according to 
the 17-segment model. Concordant signal enhancement 
in both LGE and T2-weighted sequences was considered 
as CMR positive for active cardiac involvement. LGE 
positivity in parallel with T2 negativity was rated as 
consistent with fibrotic changes.
Statistical analysis
Most data presented in here are descriptive. 
Quantitative data are presented as median, range, and 
mean ± SD.
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